Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome (for specialized target groups only)

Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news